65,437 trials
Encephalitis, Japanese B
Primary: Measles Seropositivity at 24 and 36 Months — 98.92; 95.75; 94.37; 94.62 percentage of participants seropositive
Tooth Extraction
Primary: Histologic Percentage of Vital Bone Formation — 12.98; 16.08 percentage of vital bone
Anxiety Disorder
Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540
Chronic Sinusitis
Primary: Mean Intra-patient Change in SNOT-20 Score at 24 Weeks Post-procedure Compared to Baseline — -1.25; -1.35 scores on a scale
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Atopic Dermatitis
Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 104; 121; 67 participants
Astigmatism · Myopia
Primary: Lens Orientation in Recumbent Position — 15.8; 35.2; 19.4; 29.1 degrees
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) — 2 participants
Migraine
Primary: Number of Participants With Clinical Adverse Events (AEs) — 1582; 804 Participants
Coronary Bypass Graft Stenosis of Autologous Vein
Primary: Early Complications of Vascular Zone — 1; 4; 15; 5 participants — p=0.05
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (Part B) — 5.55; 2.89 Months — p=0.0030
Chronic Hepatitis C Infection
Primary: Sustained Virologic Response At 12 Weeks (SVR12) — 50 percentage of participants
Breast Cancer · Chronic Myeloproliferative Disorders · Gestational Trophoblastic Tumor
Primary: Proportion of Participants With Controlled Acute Vomiting — 20 participants — p=0.10
Anorectal Disorders
Primary: Anal Resting Pressure Change — 90.2; 71.3; 88.1; 69.6 mmHg
Surgical Wound
Primary: Time to Hemostasis (TTH) — 21.4; 4.8 minutes